MCID: CNN001
MIFTS: 38

Cannabis Dependence

Categories: Mental diseases

Aliases & Classifications for Cannabis Dependence

MalaCards integrated aliases for Cannabis Dependence:

Name: Cannabis Dependence 12 74 54 15 17 71
Marijuana Abuse 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1849
ICD9CM 34 304.3
MeSH 43 D002189
NCIt 49 C34445
SNOMED-CT 67 85005007
ICD10 32 F12.2
UMLS 71 C0006870 C0024809

Summaries for Cannabis Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of cannabis despite problems related to use of the substance.

MalaCards based summary : Cannabis Dependence, also known as marijuana abuse, is related to withdrawal disorder and drug dependence. An important gene associated with Cannabis Dependence is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways is GABAergic synapse. The drugs Risperidone and Buspirone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotype is behavior/neurological.

Wikipedia : 74 Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is defined in the... more...

Related Diseases for Cannabis Dependence

Diseases related to Cannabis Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 withdrawal disorder 30.8 PENK FAAH CNR1
2 drug dependence 30.6 PENK GABRA2 CNR1
3 cocaine dependence 30.6 GABRA2 COMT CNR1
4 substance abuse 30.5 WASF1 GABRA2 COMT CNR1
5 alcohol dependence 30.5 HCRT GABRA2 FAAH COMT CNR1
6 substance dependence 30.5 WASF1 GABRA2 COMT CNR1
7 tobacco addiction 30.3 WASF1 GABRA2 COMT CNR1
8 polysubstance abuse 30.2 FAAH COMT CNR1
9 alcohol use disorder 30.1 WASF1 GABRA2 COMT
10 schizophreniform disorder 30.1 NRG1 COMT CNR1
11 antisocial personality disorder 30.0 WASF1 GABRA2 COMT
12 eating disorder 30.0 HCRT FAAH COMT CNR1
13 anxiety 30.0 HCRT GABRA2 FAAH COMT CNR1
14 major depressive disorder 29.8 NRG1 HCRT COMT CNR1 ABCB1
15 dysthymic disorder 29.5 WASF1 HCRT
16 cannabis abuse 29.2 WASF1 NRG1 NAPEPLD MGLL GABRA2 FAAH
17 bipolar disorder 28.8 NRG1 GABRA2 CSMD1 COMT CNR1
18 schizophrenia 28.0 NRG1 HCRT GABRA2 FAAH CSMD1 COMT
19 uvulitis 10.4 MGLL CNR1
20 drug psychosis 10.4 COMT CNR1
21 drug-induced mental disorder 10.3 COMT CNR1
22 chronic pain 10.3 COMT CNR1
23 autoimmune encephalitis 10.3 HCRT FAAH CNR1
24 substance-induced psychosis 10.3 COMT CNR1
25 paralytic ileus 10.2 CNR1 ABCB1
26 opioid addiction 10.2 COMT ABCB1
27 smoking as a quantitative trait locus 3 10.2
28 barbiturate abuse 10.2 WASF1 HCRT
29 personality disorder 10.2
30 pain agnosia 10.2 PENK MGLL FAAH CNR1
31 agnosia 10.1 PENK MGLL FAAH CNR1
32 conduct disorder 10.1
33 post-traumatic stress disorder 10.1 NRG1 FAAH COMT CNR1
34 schizotypal personality disorder 10.1 WASF1 NRG1 COMT
35 mental depression 10.1
36 opiate dependence 10.1
37 depression 10.1
38 visual epilepsy 10.0
39 cerebrovascular disease 10.0
40 seizure disorder 10.0
41 migraine with or without aura 1 10.0 HCRT FAAH COMT CNR1
42 avoidant personality disorder 10.0
43 psychotic disorder 10.0
44 severe combined immunodeficiency 10.0
45 impulse control disorder 10.0 WASF1 COMT
46 anorexia nervosa 10.0 HCRT COMT CNR1
47 specific developmental disorder 10.0 WASF1 FAAH COMT CNR1
48 social phobia 9.9
49 mood disorder 9.9
50 heroin dependence 9.9

Graphical network of the top 20 diseases related to Cannabis Dependence:



Diseases related to Cannabis Dependence

Symptoms & Phenotypes for Cannabis Dependence

MGI Mouse Phenotypes related to Cannabis Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.36 ABCB1 ANKFN1 CNR1 COMT CSMD1 FAAH

Drugs & Therapeutics for Cannabis Dependence

Drugs for Cannabis Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
2
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
3
Clozapine Approved Phase 4 5786-21-0 2818
4
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
5
Topiramate Approved Phase 4 97240-79-4 5284627
6
Haloperidol Approved Phase 4 52-86-8 3559
7
Ondansetron Approved Phase 4 99614-02-5 4595
8 Anti-Anxiety Agents Phase 4
9 Tranquilizing Agents Phase 4
10 Anticonvulsants Phase 4
11 Antipsychotic Agents Phase 4
12 Antidepressive Agents Phase 4
13 Quetiapine Fumarate Phase 4 111974-72-2
14 GABA Agents Phase 4
15 Antiemetics Phase 4
16 Gastrointestinal Agents Phase 4
17 Dopamine Antagonists Phase 4
18 Serotonin Agents Phase 4
19 Serotonin Antagonists Phase 4
20 Serotonin Receptor Agonists Phase 4
21 Cytochrome P-450 Enzyme Inhibitors Phase 4
22 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
23 Serotonin Uptake Inhibitors Phase 4
24 Dermatologic Agents Phase 4
25 Hypoglycemic Agents Phase 4
26 Haloperidol decanoate Phase 4
27 Antipruritics Phase 4
28 Neurotransmitter Agents Phase 4
29 Adrenergic Agents Phase 4
30 Atomoxetine Hydrochloride Phase 4
31
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
32
Lofexidine Approved, Investigational Phase 2, Phase 3 31036-80-3 30668
33
Diphenhydramine Approved, Investigational Phase 2, Phase 3 147-24-0, 58-73-1 3100
34
Zolpidem Approved Phase 2, Phase 3 82626-48-0 5732
35
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
36
Peppermint oil Approved, Investigational Phase 3 8006-90-4
37
Peppermint Approved Phase 3
38
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
39
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
40
Nicotine Approved Phase 3 54-11-5 942 89594
41
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
42
Amphetamine Approved, Illicit, Investigational Phase 2, Phase 3 300-62-9 5826 3007
43
Vortioxetine Approved, Investigational Phase 2, Phase 3 508233-74-7 9966051
44
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
45
Dronabinol Approved, Illicit Phase 2, Phase 3 1972-08-3 16078
46
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
47
Cysteine Approved, Nutraceutical Phase 2, Phase 3 52-90-4 5862
48 Nabiximols Investigational Phase 3 56575-23-6
49
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
50 Antimanic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 319)
# Name Status NCT ID Phase Drugs
1 N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Unknown status NCT03221231 Phase 4 N-acetylcysteine;Placebo Oral Tablet
2 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Completed NCT01153490 Phase 4
3 Clozapine for Cannabis Use Disorder in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
4 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
5 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
6 Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial Completed NCT03056482 Phase 4 Ondansetron 8mg;Haloperidol 0.05mg/kg;Haloperidol 0.1mg/kg
7 Cannabis and Schizophrenia: Effects of Clozapine Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
8 Nicotine for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
9 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
10 An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse. Terminated NCT00687609 Phase 4 Atomoxetine
11 Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II) Unknown status NCT00673647 Phase 3
12 Reducing Injury, ETOH and THC Use Among ED Patients Unknown status NCT00547963 Phase 2, Phase 3
13 Family and Group Therapies for Adolescent Alcohol Abuse Unknown status NCT00484367 Phase 2, Phase 3
14 A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
15 Facilitating the Behavioral Treatment of Cannabis Use Disorder Completed NCT02946489 Phase 2, Phase 3 CI-581a
16 Nabilone for Cannabis Dependence: A Pilot Study Completed NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
17 Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) Completed NCT01675661 Phase 3 N-Acetylcysteine;Placebo
18 A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal Completed NCT01025700 Phase 2, Phase 3 Cesemat
19 Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana Completed NCT01473719 Phase 3
20 A Brief Marijuana Intervention for Adolescent Women Completed NCT00227864 Phase 3
21 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
22 Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents Completed NCT00218114 Phase 3 Divalproex Sodium;Placebo
23 Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With Temporomandibular Disorders: a Randomized, Double-blind Study Completed NCT03994640 Phase 2, Phase 3
24 The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury Completed NCT01555983 Phase 2, Phase 3 Vaporization of Cannabis
25 A Double Blind, Randomised, Three Way Crossover Study Comparing Two Different Sublingual Cannabis Based Medicine Extracts With Placebo, in Patients With Chronic Pain Due to Brachial Plexus Injury. Completed NCT01606189 Phase 3 GW-1000-02;GW-2000-02;Placebo
26 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT01109563 Phase 3
27 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Recruiting NCT02803229 Phase 2, Phase 3 Adderall-XR;Matched placebo
28 Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study Recruiting NCT03485274 Phase 2, Phase 3 Vortioxetine
29 N-Acetylcysteine for Youth Cannabis Use Disorder Recruiting NCT03055377 Phase 2, Phase 3 N-acetyl cysteine;Placebo oral capsule
30 Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Recruiting NCT03481959 Phase 3 Methylphenidate
31 Vaping THC From Electronic Cigarettes: a Novel Evaluation of Intake and Pharmacokinetics Recruiting NCT02955329 Phase 3 Nicotine only;THC only;Nicotine and THC
32 Safety and Efficacy of PPP011-kit for Improving Health Related Quality of Life in Patients With Advanced Cancer and Uncontrolled Symptoms: A Randomized, Double-blind, Placebo-Controlled, Parallel Group Study Not yet recruiting NCT04001010 Phase 3 PPP011;Placebo
33 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study to Investigate the Safety and Efficacy of Cannabis Oil in Maintenance Hemodialysis Patients With Protein-energy Wasting Not yet recruiting NCT03664141 Phase 3 Cannabis oil;Placebo/ Regular Oil
34 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Terminated NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
35 CANDIS -Targeted Treatment for Cannabis Disorders Unknown status NCT00252980 Phase 2
36 Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction Unknown status NCT00543036 Phase 1, Phase 2
37 Randomized and Double-blind Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
38 Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study Unknown status NCT02083874 Phase 2 CBD
39 A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
40 The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer Unknown status NCT03245658 Phase 2 THC and CBD Mixture
41 Gabapentin for Cannabis Withdrawal and Use Completed NCT00395044 Phase 2 Placebo;Gabapentin
42 Gabapentin Treatment of Cannabis Dependence Completed NCT00974376 Phase 2 gabapentin 1200mg/day;Placebo
43 Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence Completed NCT00954681 Phase 2 quetiapine
44 A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence. Completed NCT02044809 Phase 2 Cannabidiol;Placebo
45 Translational Center on the Clinical Neurobiology of Cannabis Addiction Completed NCT00656487 Phase 2 rimonabant;placebo
46 A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction Completed NCT00217971 Phase 2 Dronabinol;Placebo
47 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence Completed NCT02210195 Phase 2 aprepitant;Placebo
48 An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents Completed NCT00542750 Phase 1, Phase 2 N-Acetylcysteine
49 Pharmacological Treatment of Cannabis Withdrawal and Dependence Completed NCT01611948 Phase 2 Aprepitant;Placebo
50 A Controlled Trial of N-Acetylcysteine (NAC) in Cannabis Dependent Adolescents Completed NCT01005810 Phase 2 N-Acetylcysteine;placebo

Search NIH Clinical Center for Cannabis Dependence

Cochrane evidence based reviews: marijuana abuse

Genetic Tests for Cannabis Dependence

Anatomical Context for Cannabis Dependence

MalaCards organs/tissues related to Cannabis Dependence:

40
Brain, Testes, Eye, Lung, Cortex, Spinal Cord, Breast

Publications for Cannabis Dependence

Articles related to Cannabis Dependence:

(show top 50) (show all 781)
# Title Authors PMID Year
1
The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. 54 61
19443135 2009
2
Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. 54 61
19016476 2009
3
An autosomal linkage scan for cannabis use disorders in the nicotine addiction genetics project. 54 61
18519829 2008
4
Marijuana, immunity and infection. 54 61
9610678 1998
5
Cannabis-dependent adolescents show differences in global reward-associated network topology: A functional connectomics approach. 61
30957353 2020
6
Medical cannabis for chronic pain: can it make a difference in pain management? 61
31535218 2020
7
Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale nationally representative study. 61
31916333 2020
8
Exploratory analysis of genetic variants influencing molecular traits in cerebral cortex of suicide completers. 61
31418530 2020
9
Does Cannabis Dependence Add on to the Neurocognitive Impairment Among Patients With Opioid Dependence? A Cross-Sectional Comparative Study. 61
31951069 2020
10
Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence. 61
31904784 2020
11
Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence. 61
31904785 2020
12
Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence-Reply. 61
31904790 2020
13
Personality disorders and social support in cannabis dependence: A comparison with alcohol dependence. 61
31957689 2020
14
[Why and how keep in mind cannabis in our smoking outpatients?] 61
30598304 2020
15
Problems with defining cannabis dependence. 61
31634166 2020
16
Neuroanatomical alterations in people with high and low cannabis dependence. 61
31298035 2020
17
Influence of the type of childhood violence on cannabis abuse and dependence among adolescents: a systematic review and meta-analysis. 61
30627731 2020
18
Older Adults Driving Under the Influence: Associations With Marijuana Use, Marijuana Use Disorder, and Risk Perceptions. 61
29199501 2019
19
Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002-2016. 61
31698323 2019
20
Cortical surface morphology in long-term cannabis users: A multi-site MRI study. 61
30558823 2019
21
Cannabis use among women of reproductive age in the United States: 2002-2017. 61
31421581 2019
22
Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. 61
31808250 2019
23
Modes of cannabis use: A secondary analysis of an intensive longitudinal natural history study. 61
31326775 2019
24
Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. 61
31586809 2019
25
Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. 61
30747847 2019
26
Cannabis Dependence or Abuse in Kidney Transplantation: One Perspective. 61
30747855 2019
27
Brain structural changes in cannabis dependence: association with MAGL. 61
31695165 2019
28
Brain-Derived Neurotrophic Factor and Oxidative Stress in Cannabis Dependence. 61
31779002 2019
29
Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries: A Retrospective Cohort Analysis. 61
31789638 2019
30
"Side Effects" Observed Within ~1-90 Days After Cannabis Onset: Epidemiological Estimates for the United States, 2004-2014. 61
31487092 2019
31
Synergistic effects of marijuana abuse and HIV infection on neural activation during a cognitive interference task. 61
30239074 2019
32
Cannabis use and Associated Health Problems – What’s the Harm? 61
31651130 2019
33
Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. 61
31607281 2019
34
Cannabis Use Disorder and Post-Deployment Suicide Attempts in Iraq/Afghanistan-Era Veterans. 61
29952737 2019
35
The limitations associated with measuring cannabis dependence, a response to Budney and colleagues. 61
30927076 2019
36
Reward, Control & Decision-Making in Cannabis Use Disorder: Insights from Functional MRI. 61
31364398 2019
37
Impaired cognitive performance under psychosocial stress in cannabis-dependent men is associated with attenuated precuneus activity 61
31509368 2019
38
A Smartphone Attention Bias App for Individuals With Addictive Disorders: Feasibility and Acceptability Study. 61
31586359 2019
39
Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. 61
31375922 2019
40
Alteration to hippocampal volume and shape confined to cannabis dependence: a multi-site study. 61
30022573 2019
41
Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. 61
31305874 2019
42
[MEDICAL MARIJUANA DEPENDENCE AMONG CHRONIC PAIN PATIENTS SUFFERING FROM DEPRESSION AND ANXIETY]. 61
31339242 2019
43
Reduced Segregation Between Cognitive and Emotional Processes in Cannabis Dependence. 61
31211388 2019
44
Marijuana Induced Sick Sinus Syndrome: A Case Report. 61
31227686 2019
45
Cannabis Abuse or Dependence During Pregnancy: A Population-Based Cohort Study on 12 Million Births. 61
30448107 2019
46
Relative effectiveness of N-acetylcysteine and baclofen as anticraving agents in cannabis dependence - A retrospective study with telephonic follow-up. 61
31142898 2019
47
[Characteristics of cannabis users in a French family practice]. 61
30954323 2019
48
Substance type moderates the longitudinal association between depression and substance use from pre-treatment through a 1-year follow-up. 61
30784954 2019
49
Trace Detection of Tetrahydrocannabinol in Body Fluid via Surface-Enhanced Raman Scattering and Principal Component Analysis. 61
30907578 2019
50
Marijuana smoking and markers of testicular function among men from a fertility centre. 61
30726923 2019

Variations for Cannabis Dependence

Expression for Cannabis Dependence

Search GEO for disease gene expression data for Cannabis Dependence.

Pathways for Cannabis Dependence

Pathways related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.54 NAPEPLD MGLL GABRA2 FAAH CNR1

GO Terms for Cannabis Dependence

Cellular components related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GABA-ergic synapse GO:0098982 9.13 NRG1 GABRA2 CNR1
2 axon GO:0030424 9.02 PENK NRG1 GABRA2 COMT CNR1

Biological processes related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 temperature homeostasis GO:0001659 9.16 NAPEPLD HCRT
2 startle response GO:0001964 8.96 PENK CSMD1
3 monoacylglycerol catabolic process GO:0052651 8.62 MGLL FAAH

Molecular functions related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 acylglycerol lipase activity GO:0047372 8.62 MGLL FAAH

Sources for Cannabis Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....